Profile
Bruno Besse is currently the Chief Medical Officer at Quantum Genomics SA. He previously worked as a Principal at Roche Diagnostics GmbH, Head-Medical Affairs at Crossject SA, and Principal at Aventis Pharma SARL. Dr. Besse completed his undergraduate degree at INSEAD and holds a doctorate from Université de Paris XI Paris Sud.
Bruno Besse active positions
| Companies | Position | Start |
|---|---|---|
| QUANTUM GENOMICS | Chief Tech/Sci/R&D Officer | 2017-02-28 |
Former positions of Bruno Besse
| Companies | Position | End |
|---|---|---|
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops innovative medicines, treatments and diagnostics | Corporate Officer/Principal | - |
Aventis Pharma SARL
Aventis Pharma SARL Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Corporate Officer/Principal | - |
| CROSSJECT | Chief Tech/Sci/R&D Officer | - |
Training of Bruno Besse
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Roche Diagnostics GmbH
Roche Diagnostics GmbH Miscellaneous Commercial ServicesCommercial Services Develops innovative medicines, treatments and diagnostics | Commercial Services |
Crossject SA
Crossject SA Medical SpecialtiesHealth Technology Designs and develops needle free, pre-filled single-use injection systems | Health Technology |
Aventis Pharma SARL
Aventis Pharma SARL Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
INSEAD
INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Université de Paris XI Paris Sud
Université de Paris XI Paris Sud Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Quantum Genomics SA
Quantum Genomics SA Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies for cardiovascular diseases | Health Technology |
- Stock Market
- Insiders
- Bruno Besse
















